Skip to Content

Clinical Trials & Research

Clinical trials are research studies that have been carefully designed to answer questions about new ways to prevent cancer, treat cancer, and manage side effects of treatment.

The Hall-Perrine Cancer Center participates in national clinical trials through the National Cancer Institute (NCI) and national and international studies through the pharmaceutical industry. These types of clinical trials are leading to major breakthroughs in cancer treatment in our own community.

Through the Iowa-Wide Oncology Research Coalition (I-WORC), Oncology Associates at Mercy Medical Center actively participates in more than 45 clinical trials at any given time. This allows a great number of patients access to trials based on the cancer and stage of cancer.

For more information about clinical trials, contact Tami Mason, BSN at (319) 363-2690 ext. 2 or

Current Clinical Trials Available at Hall-Perrine Cancer Center



Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma. Learn more.



Waiting on credentialing: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer. Learn more.

A011106 (ALLIANCE):

ALTernate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study (NCT01953588). Learn more.


Rand Ph III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Br Ca Pts (CT1-3N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy. Learn more.


Ph III Rand, Double-Blind, Placebo-Controlled Study to Assess the Efficacy & Safety of Olaparib Vs Placebo as Adjuvant TX in Pts w/ Germline BRCA 1/2 Mutations & High Risk HER2 Neg Primary Br Ca Who Have Completed Definitive Local TX & Neoadjuvant or Adjuvant Chemo. Learn more.


Rand Ph III Trial of Adjuvant Therapy Comparing Doxorubicin + Cyclophosphamide Followed by Weekly Paclitaxel w/ or w/o Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Br Ca. Learn more.


1st/2nd line: Rand Ph III Trial of Endocrine Therapy Plus Entinostat / Placebo in Patients w/ Hormone Receptor-Positive Advanced Breast Cancer. Learn more.


(JIT) 2nd line: MM-302 plus Trastuzumab vs. Chemotherapy of Physicians Choice, in Locally Advanced/Metastatic Her 2+ Breast Cancer. Learn more.


Front line for recurrent: A Randomized, Double Blind, Placebo-controlled phase 2 study of Paclitaxel in combination with reparixin compared to Paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (FRIDA). Learn more.


1st/2nd line: A Rand Ph III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer


Ph III Rand, Placebo-Controlled Trial Evaluating Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Pts w/ High-Risk, Hormone Receptor-Positive & HER2/NEU Negative Breast Cancer


Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT). Learn more.


Impact of Conservation Surgery on Surgical Outcomes and Cosmesis in Pts w/ Multiple Ipsilateral Breast Cancers. Learn more.



Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND# 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors. ***Effective Tuesday, October 6, 2015 at 4:30 PM EST, Alliance A021202 Will Temporarily Suspend New Patient Accrual***. Learn more.

EMR 100070-007*:

A phase 3 open-label, multicenter trial of maintenance therapy with avelumab vs continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic adenocarcinoma of the stomach, or of the gastro-esophageal junction. Learn more.


Rand Ph II Study of Irinotecan & C225 w/ or w/o the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemo. Learn more.


Ph II/III Neoadjuvant FOLFOX w/ Selective Use of Combined Modality Chemoradiation Vs Preop Combined Modality Chemoradiation for Locally Advanced Rectal Ca Pts Undergoing Low Anterior Resection w/ Total Mesorectal Excision. Learn more.

XBiotech 2012-PT023(JIT):

A Phase III Double-blinded, placebo controlled study of Xilonix for improving survival in metastatic colorectal cancer. Learn more.



Ph III Trial of Enzalutamide vs Enzalutamide, Abiraterone & Prednisone for Castration Resistant Metastatic Prostate Cancer

NRG RTOG-0924:

Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Learn more.


Double-Blind Placebo-Controlled Trial of Eflornithine & Sulindac to Prevent Recurrence of High Risk Adenomas & Second Primary Colorectal Cancers in Pts w/ Stage 0-III Colon or Rectal Ca, Ph III- Preventing Adenomas of the Colon w/ Eflornithine & Sulindac (PACES). Learn more.


A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer. Learn more.


EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Ph III Study (CLOSES 9/15/16)


NRG GOG-0238:

A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus. Learn more.


A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer. Learn more.

NRG RTOG-0724:

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy. Learn more.

Head and Neck

NRG RTOG-0920:

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer. Learn more.



Rand Ph III Trial of Bortezomib, LENalidomide & Dexamethasone (VRd) Vs. Carfilzomib, Lenalidomide & Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE). Learn more.


Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB -->R); Arm B = Rituximab+Bendamustine+Bortezomib Followed by Rituximab Consolidation (RBV--> R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB --> LR) or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV --> LR). Learn more.


Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma. Learn more.


Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma. Learn more.

IPI-145-06 (JIT):

A phase 2 study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma. Learn more.


Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT). Learn more.



Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). Learn more.


Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Learn more.


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. Learn more.


Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers. Learn more.


Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer. Learn more.


(NRG) Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC (NCT02186847. Learn more.

NRG RTOG-1306:

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC). Learn more.


More information coming soon!



Efficacy and Safety 0f Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism. Learn more.


Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND# 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors. ***Effective Tuesday, October 6, 2015 at 4:30 PM EST, Alliance A021202 Will Temporarily Suspend New Patient Accrual***. Learn more.


Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias. Learn more.


Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Symptom Management/Cancer Control

More information coming soon!


More information coming soon!

Please note: Participation in clinical trials require that participants meet very specific eligibility criteria. Please check with your physician to see if you may be eligible. This website is periodically updated to list studies currently available. Please speak with your doctor to inquire if a particular clinical trial is currently enrolling patients.

American Cancer Society

Clinical Trials Matching Service is a free, confidential program that helps patients, their families and healthcare professionals find cancer clinical trials most appropriate to a specific patient, taking their medical and personal history in consideration. For more information, call 1-800-303-5691 or visit

National Cancer Institute

The National Cancer Institute (NCI) offers a clinical trials search feature along with patient education on clinical trials. For more information, go to

S1207: Ph III Rand, Placebo-Controlled Trial Evaluating Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Pts w/ High-Risk, Hormone Receptor-Positive & HER2/NEU Negative Breast Cancer:

Have A Question?

Treatment options, finding physicians or seeking second opinions? Let us help you find the answers. Contact us.

Courageous Stories

Suzanne Staab

Suzanne's Story

In keeping with tradition at Hall-Perrine, Suzanne Staab – with family, friends and Mercy staff by her side – rings a bell to signify the end of her cancer treatment. Watch her story.

To discuss treatments call (319) 365-HOPE (4673)